This experiment was conducted to investigate the anti-tumor activities of anti-BCMA-CAR2 and anti-BCMA-CAR3 T against BCMA-expressing multiple myeloma (MM) cell lines. Here, TNFRSF17 is linked to plasma cell myeloma.